FAKNOSTICS, LLC

PHOENIX, AZ

OncologyGrant-only

What changed

NIH R01 · $0.8M · Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome

10mo agoGrant renewalAug 27, 2025Source filing (opens the source filing in a new tab)

Momentum

41no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R42 · $664k · non-dilutive
Sep 15, 2024
FAKNOSTICS, LLC · PI MARLOWE, TIMOTHY A · NIDDK · award ends Aug 31, 2028 · Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis
NIH RePORTER · NIH RePORTER 11249902 (opens the source filing in a new tab)
Grant
R01 · $751k · non-dilutive
Sep 1, 2023
UNIVERSITY OF ARIZONA · PI FALLON, MICHAEL B · NHLBI · award ends Jun 30, 2027 · Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome
NIH RePORTER · NIH RePORTER 11115808 (opens the source filing in a new tab)
Grant
R42 · $663k · non-dilutive
Aug 10, 2022
FAKNOSTICS, LLC · PI MARLOWE, TIMOTHY A · NHLBI · award ends Jul 31, 2027 · Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
NIH RePORTER · NIH RePORTER 11180503 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 1.00{"reasons":["name similarity 100%","semantic similarity 83%","shared principal investigator / founder","same city"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the grant record at 0.28{"reasons":["same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R01 · $0.8M · Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R42 · $0.7M · Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R42 · $0.7M · Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis
11mo agoGrant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R42 · $664k · non-dilutive

R01 · $751k · non-dilutive

R42 · $663k · non-dilutive